Please login to the form below

Not currently logged in
Email:
Password:

Pfizer agrees MoU with Chinese firm

Pfizer has signed a memorandum of understanding (MoU) with Shanghai Pharmaceuticals Co

Pfizer has signed a memorandum of understanding (MoU) with Shanghai Pharmaceuticals Co that includes selling and distributing an unnamed Pfizer product in China. 

The companies plan to explore future co-operation opportunities, including further distribution and commercialisation, research and development activities, manufacturing and equity investment opportunities. 

The companies also expect to strengthen their existing co-operation for the promotion of Pfizer's Prevenar (7-valent) a pneumococcal conjugate vaccine, approved for use in China for active immunisation of infants and toddlers for the prevention of invasive diseases caused by the bacterium Streptococcus pneumonia. 

David Simmons, president and general manager, emerging markets and established products of Pfizer, said: "Our intent to explore a range of business opportunities with Shanghai Pharmaceutical is an example of our commitment to expand our presence in China in collaboration with the local industry." 

Shanghai Pharmaceutical has been one of Pfizer's major partners in China for years and is its largest distribution customer in the market.

21st April 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
OPEN Access Consulting

OPEN Access Consulting is a specialist market access agency within the OPEN Health Group. As value communications experts we specialise...

Latest intelligence

Where next in Alzheimer’s disease R&D?
How past failures and emerging biology are reshaping drug development...
Brain scan
Brain power: fresh approaches to Alzheimer’s drug discovery
New alliances are learning from past mistakes and breaking down research barriers...
Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...

Infographics